Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle

Oncogene volume 19, pages 2870–2876 (2000)Cite this article

Abstract

Assembly and activity of the proto-oncogenic cyclin D/CDK4(6) complexes, the major driving force of G1 phase progression, is negatively regulated by a family of INK4 CDK inhibitors p16INK4a, p15INK4b, p18INK4c, and p19INK4d. Expression of the INK4 family members is controlled at the transcriptional level, through differential response to environmental and intracellular signals such as cytokines, oncogenic overload, or cellular senescence. Here we show that the periodic oscillation of the p19INK4d protein during the cell cycle is determined by the ubiquitin/proteasome-dependent mechanism, allowing the protein abundance to follow the changes in its mRNA expression. Within the INK4 family, this regulatory mode appears restricted to p19INK4d whose ubiquitination was dependent on the integrity of lysine 62, and binding to CDK4. These results highlight unexpected differences among the INK4 inhibitors, and suggest how p19INK4d may help regulate the rate of cyclin D/CDK4(6) complex formation, and thereby timely progression through the mammalian cell division cycle.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Alevizopoulos K, Vlach J, Hennecke S and Amati B . 1997 EMBO J 16: 5322–5333

  • Amati B and Vlach J . 1999 Nat Cell Biol 1: E91–E93

  • Bartek J, Bartkova J and Lukas J . 1996 Curr Opin Cell Biol 8: 805–814

  • Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J . 1996 Cancer Res 56: 5475–5483

  • Bartkova J, Lukas J, Strauss M and Bartek J . 1998 Oncogene 17: 1027–1037

  • Carrano AC, Eytan E, Hershko A and Pagano M . 1999 Nat Cell Biol 1: 193–199

  • Chan FKM, Zhang J, Cheng L, Shapiro DN and Winoto A . 1995 Mol Cell Biol 15: 2682–2688

  • Ciechanover A . 1998 EMBO J 17: 7151–7160

  • Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A . 1997 Cancer Res 57: 3381–3385

  • Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG and Xiong Y . 1994 Genes Dev 8: 2939–2952

  • Haas K, Staller P, Geisen C, Bartek J, Eilers M and Möröy T . 1997 Oncogene 15: 179–192

  • Hannon G and Beach D . 1994 Nature 371: 257–261

  • Hirai H, Roussel MF, Kato J, Ashmun RA and Sherr CJ . 1995 Mol Cell Biol 15: 2672–2681

  • Jiang H, Chou HS and Zhu L . 1998 Mol Cell Biol 18: 5284–5290

  • Koh J, Enders GH, Dynlacht B and Harlow E . 1995 Nature 375: 506–510

  • Lees E . 1995 Curr Opin Cell Biol 7: 773–780

  • Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M . 1997 Nat Med 3: 231–234

  • Lukas C, Jensen SS, Bartkova J, Lukas J and Bartek J . 1999 Hybridoma 18: 225–234

  • Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J . 1995a Mol Cell Biol 15: 2600–2611

  • Lukas J, Bartkova J, Welcker M, Petersen OV, Peters G, Strauss M and Bartek J . 1995b Oncogene 10: 2125–2134

  • Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI and Bartek J . 1997 Genes Dev 11: 1479–1492

  • Lukas J, Pagano M, Staskova Z, Draetta G and Bartek J . 1994 Oncogene 9: 707–718

  • Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J . 1995c Nature 375: 503–506

  • Lukas J, Sorensen CS, Lukas C, Santoni-Rugiu E and Bartek J . 1999 Oncogene 18: 3930–3935

  • McConnell BB, Gregory FJ, Stott FJ, Hara E and Peters G . 1999 Mol Cell Biol 19: 1981–1989

  • Medema RH, Herrera RE, Lam F and Weinberg RA . 1995 Proc Natl Acad Sci USA 92: 6289–6293

  • Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A and Pagano M . 1999 Genes Dev 13: 1181–1189

  • Parry D, Bates S, Mann DJ and Peters G . 1995 EMBO J 14: 503–511

  • Pavey S, Conroy S, Russell T and Gabrielli B . 1999 Cancer Res 59: 4185–4189

  • Reynisdottir I, Polyak K, Iavarone A and Massague J . 1995 Genes Dev 9: 1831–1845

  • Roussel MF . 1999 Oncogene 18: 5311–5317

  • Ruas M and Peters G . 1998 Biochim Biophys Acta F115–F177

  • Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM and Stampfer MR . 1997 Mol Cell Biol 17: 2458–2467

  • Serrano M . 1997 Exp Cell Res 237: 7–13

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . 1997 Cell 88: 593–602

  • Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen EM and Rollins BJ . 1995 Cancer Res 55: 6200–6209

  • Sherr CJ . 1996 Science 274: 1672–1677

  • Sherr CJ and Roberts JM . 1999 Genes Dev 13: 1501–1512

  • Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U and Krek W . 1999 Nat Cell Biol 1: 207–214

  • Tassan JP, Schultz SJ, Bartek J and Nigg EA . 1994 J Cell Biol 127: 467–478

  • Thullberg M, Welcker M, Bartkova J, Kjerulff A A, Lukas J, Högberg J and Bartek J . 2000 Hybridoma 19: 63–72

  • Treier M, Staszewski LM and Bohmann D . 1994 Cell 78: 787–798

  • Van den Heuvel S and Harlow E . 1993 Science 262: 2050–2054

  • Welcker M, Lukas J, Strauss M and Bartek J . 1996 Oncogene 13: 419–425

  • Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde K-G and Beach DA . 1995 Science 269: 1281–1284

  • Wölff B and Naumann M . 1999 Oncogene 18: 2663–2666

  • Zindy F, Quelle DE, Roussel MF and Sherr CJ . 1997 Oncogene 15: 203–211

Download references

Acknowledgements

We wish to thank G Evan, NE Fusenig, K Helin, M Pagano, S Reed, M Seto, J Shay, C Ward and A Winoto for generous gift of some reagents, and M Welcker for his advice with the ubiquitination assays. This work was supported by grants from the Danish Cancer Society, The Danish Medical Research Council, and the Human Frontier Science Program.

Author information

Authors and Affiliations

  1. Danish Cancer Society, Institute of Cancer Biology, Strandboulevarden 49, Copenhagen Ø, DK-2100, Denmark

    Minna Thullberg, Jiri Bartek & Jiri Lukas

Authors
  1. Minna Thullberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiri Bartek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiri Lukas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thullberg, M., Bartek, J. & Lukas, J. Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle. Oncogene 19, 2870–2876 (2000). https://doi.org/10.1038/sj.onc.1203579

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203579

Keywords

This article is cited by

Search

Advanced search

Quick links